EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.

Studied

This full-text EASL-EASD-EASO guideline updated definitions, screening, diagnosis, prevention, and treatment recommendations for metabolic dysfunction-associated steatotic liver disease.

Who / model

The guidance concerns adults with or at risk for MASLD, especially people with type 2 diabetes, abdominal obesity plus another metabolic risk factor, or abnormal liver tests.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

It recommends stepwise fibrosis assessment with FIB-4 followed by elastography when indicated. GLP-1 drugs may be used for diabetes or obesity, but were not recommended as MASH-targeted therapy without phase 3 histology evidence.

Limits

Recommendations combined graded evidence with expert consensus; some guidance was created despite limited supporting literature.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary